This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsShort InterestTrendsBuy This Stock XTLB vs. CCM, PRPH, NNVC, VVOS, ALLR, RLYB, MBRX, SABS, FBLG, and LIXTShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Concord Medical Services (CCM), ProPhase Labs (PRPH), NanoViricides (NNVC), Vivos Therapeutics (VVOS), Allarity Therapeutics (ALLR), Rallybio (RLYB), Moleculin Biotech (MBRX), SAB Biotherapeutics (SABS), FibroBiologics (FBLG), and Lixte Biotechnology (LIXT). These companies are all part of the "medical" sector. XTL Biopharmaceuticals vs. Its Competitors Concord Medical Services ProPhase Labs NanoViricides Vivos Therapeutics Allarity Therapeutics Rallybio Moleculin Biotech SAB Biotherapeutics FibroBiologics Lixte Biotechnology Concord Medical Services (NYSE:CCM) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Do insiders & institutionals have more ownership in CCM or XTLB? 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer CCM or XTLB? In the previous week, Concord Medical Services had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Concord Medical Services and 1 mentions for XTL Biopharmaceuticals. Concord Medical Services' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Concord Medical Services Neutral XTL Biopharmaceuticals Neutral Which has more volatility and risk, CCM or XTLB? Concord Medical Services has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Which has preferable valuation & earnings, CCM or XTLB? XTL Biopharmaceuticals has lower revenue, but higher earnings than Concord Medical Services. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConcord Medical Services$52.60M0.50-$42.23MN/AN/AXTL Biopharmaceuticals$450K16.23-$1.03MN/AN/A Is CCM or XTLB more profitable? Company Net Margins Return on Equity Return on Assets Concord Medical ServicesN/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A Do analysts prefer CCM or XTLB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryConcord Medical Services and XTL Biopharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.63M$415.98M$6.04B$10.45BDividend YieldN/A2.45%5.73%4.82%P/E RatioN/A7.2185.1427.26Price / Sales16.233.36590.92134.18Price / CashN/A8.4125.7730.18Price / Book1.340.8912.666.76Net Income-$1.03M$10.55M$3.32B$276.50M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.2806 of 5 stars$1.34+18.6%N/AN/A$7.63M$450K0.00N/ACCMConcord Medical Services0.7023 of 5 stars$5.57-2.4%N/A-16.6%$24.75M$52.60M0.00970High Trading VolumePRPHProPhase Labs1.1518 of 5 stars$0.61+2.1%N/A-78.8%$24.73M$6.77M-0.48130NNVCNanoViricides0.093 of 5 stars$1.42-2.4%N/A-8.7%$24.67MN/A-1.9720VVOSVivos Therapeutics2.0189 of 5 stars$3.10-4.6%$4.92+58.6%+25.3%$24.39M$15.03M-1.85160ALLRAllarity Therapeutics2.752 of 5 stars$1.75+6.1%$9.25+428.6%+10.1%$23.97MN/A0.0010RLYBRallybio3.0235 of 5 stars$0.56-2.4%$5.00+792.9%-52.0%$23.97M$640K-0.6040Analyst DowngradeGap DownMBRXMoleculin Biotech2.9024 of 5 stars$0.49+0.6%$4.00+724.7%-80.8%$23.87MN/A0.0020SABSSAB Biotherapeutics4.1691 of 5 stars$2.34+2.2%$9.75+316.7%-3.7%$23.84M$1.32M-0.59140News CoverageAnalyst ForecastFBLGFibroBiologics2.6398 of 5 stars$0.49-10.8%$12.67+2,482.9%-83.1%$23.03MN/A0.0010News CoverageGap DownHigh Trading VolumeLIXTLixte Biotechnology0.5151 of 5 stars$4.97-1.6%N/A+133.3%$23.03MN/A-3.854Negative News Related Companies and Tools Related Companies Concord Medical Services Competitors ProPhase Labs Competitors NanoViricides Competitors Vivos Therapeutics Competitors Allarity Therapeutics Competitors Rallybio Competitors Moleculin Biotech Competitors SAB Biotherapeutics Competitors FibroBiologics Competitors Lixte Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
